CSV May 23, 2023 through May 24, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CHITOSAN	ASSAY/*Degree*	*USP42–NF37*	5663	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In the *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	of Deacetylation							Change Result = {1 ? [(7 × A_2)/(3 × A_1)] × 100 to: Result = {1 ? [(7 × A_2)/(3 × A_1)]} × 100
SODIUM BICARBONATE	IM PURITIES/ *Carbonate*	*USP42–NF37*	4019	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *Analysis*: Change and promptly add 10 g of sodium bicarbonate to: and promptly add 10 g of Sodium Bicarbonate
SAW PALMETTO EXTRACT	COMPOSITION /*Content of Long-Chain Alcohols and Sterols*	*USP42–NF37*	5196	28-Jun-2019	1-Jul-2019	*NA*	*NA*	In *System suitability stock solution B*: Change 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS and 0.37 mg/mL of stigmastanol to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								0.37 mg/mL of stigmastanol and 2 mg/mL each of campesterol, stigmasterol, and USP ?-Sitosterol RS in chloroform
REAGENTS AND REFERENCE TABLES	SOLUTIONS/*0.02 M Edetate Disodium VS*	*USP42–NF37*	6179	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Standardization*: Change previously dried at 100° to: previously dried at 110°
CEFTIOFUR SODIUM	IMPURITIES/*High Molecular Weight Impurities*	*USP42–NF37*	859	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Analysis*: Change r_C = peak response of ceftiofur from the *Sample solution* (mg/mL) r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(mg/mL) to: r_C = peak response of ceftiofur from the *Sample solution* r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution*
DIPHENHYDRAMINE HYDROCHLORIDE AND IBUPROFEN CAPSULES	ASSAY/*Procedure*/*Chromatographic system*/*Detectors*	*USP42–NF37*	1402	31-May-2019	1-Jun-2019	*NA*	*NA*	Change *Identification test A*: Diode array, UV 200–400 nm to: *Identification B*: Diode array, UV 200–400 nm
DULOXETINE DELAYED-RELEASE CAPSULES	ASSAY/*Procedure*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Buffer A*: Change monobasic sodium phosphate to: monobasic potassium phosphate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND In *Buffer B*: Change monobasic sodium phosphate to: monobasic ammonium phosphate
LEVOCARNITINE	IMPURITIES/ *Enantiomeric Purity*	*USP42–NF37*	2541	31-May-2019	1-Jun-2019	*NA*	*NA*	In the second equation in *Analysis*: Change Result = (R_L ? P_B)/(P_A ? P_B) to: Result = (R_L ? P_B)/(P_A ? P_B) × 100
TELMISARTAN TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4206	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Telmisartan Related Compound A RS: Change 1,7’-Dimethyl-2’-propyl-1*H*,3’*H*-2,5’-bibenzo[*d*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]imidazole. $C_{19}H_{20}N_4$ 304.39 to: 1,7’-Dimethyl-2’-propyl-1*H*,3’*H*-2,5’-bibenzo[*d*]imidazole monohydrate. $C_{19}H_{20}N_4 \cdot H_2O$ 322.41
LIQUID GLUCOSE	ASSAY/ *Reducing Sugars*	*USP42–NF37*	5741	31-May-2019	1-Jun-2019	*NA*	*NA*	In the variable definition list in *Analysis*: Change C_U = concentration of dextrose equivalent to: C_U = concentration of Liquid Glucose
ROSUVASTATIN TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 3*	*Revision Bulletin (Official April 01, 2019)*	Online	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Medium*: Change (dissolve 63.0 of citric acid to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(dissolve 63.0 g of citric acid
DACTINOMYCIN	IDENTIFICATION/*A. Ultraviolet Absorption <197U>/ Acceptance criteria*	*USP42–NF37*	1203	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Absorptivity*: Change The absorptivity of the *Sample solution* at 445 nm is NLT 95.0% and NMT 103.0% that of the *Standard solution*. to: The absorptivity, calculated on the dried basis, of the *Sample solution* at 445 nm is NLT 95.0% and NMT 103.0% that of the *Standard solution*.
DOXORUBICIN HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	In the fourth equation in *Analysis*: Change *P* = potency of doxorubicin in USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
EPRINOMECTIN	IMPURITIES/*Organic Impurities/Acceptance criteria*	*USP42–NF37*	1627	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Total unknown impurities*: Change NMT 1.0 to: NMT 1.0%
SUMATRIPTAN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4139	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Sumatriptan Succinate Related Impurities RS: Change Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1*H*-indol-5-yl]-*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-methylmethane sulfonamide maleate salt, sumatriptan succinate related compound C, [3 -[2-(dimethylami no-*N* -o xid e)ethyl]-1*H*-indol- 5-yl]-*N* -methylmethane sulfonamide, and [3-[2-(amin oethyl)]-1*H* -indo l-5-yl]-*N*-methyl methanesulfona mide. to: Mixture of sumatriptan succinate, [3-[2-(methylamino)et hyl]-1*H* -indo l-5-yl]-*N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-methylmethane sulfonamide, sumatriptan succinate related compound C, [3 -[2-(dimethylamino-*N* -oxide)ethyl]-1*H* -indol-5-yl]-*N* -methylmethane sulfonamide, and [3-[2-(aminoethyl)]-1*H* -indol-5-yl]-*N*-methyl methanesulfonamide.
BACILLUS COAGULANS	ASSAY/ *Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Sample preparation* and *Analysis*: Change peptone water to: *Peptone diluent*
ARTICLES OF	TEST FOR	*USP42–NF37*	6701	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Aflatoxin*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
BOTANICAL ORIGIN	AFLATOXINS/*Method I*							*standard solution*: Change ? = molecular absorptivity to: ? = molar absorptivity AND in paragraph 2 of *Aflatoxin standard solution*: Change transfer an accurate volume of each aflatoxin standard stock solution to: transfer an accurate volume of each aflatoxin stock solution
CETIRIZINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	897	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Cetirizine Related Compound A RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2-(2-{4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetic acid, ethyl ester dihydrochloride. $C_{23}H_{29}ClN_2O_3$ · 2HCl 489.86 to: (*RS*)-2-[2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic acid ethyl ester oxalate. $C_{23}H_{29}ClN_2O_3$ · $C_2H_2O_4$ 506.98
DIPHENHYDRAMINE HYDROCHLORIDE AND IBUPROFEN CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Analysis*	*USP42–NF37*	1402	31-May-2019	1-Jun-2019	*NA*	*NA*	Change C_S = concentration of USP Diphenhydramine Hydrochloride RS and USP Ibuprofen RS in the *Standard solution* (mg/mL) to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_S = concentration of USP Diphenhydramine Hydrochloride RS or USP Ibuprofen RS in the *Standard solution* (mg/mL)
DULOXETINE DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Test 3*/*Procedure*: Change 1 N sodium hydroxide VS. to: 0.1 N hydrochloric acid VS.
MILRINONE	ASSAY/ *Procedure*	*USP42–NF37*	2922	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Buffer*: Change 72.44 g of sodium tetraborate to: 72.44 g of sodium tetraborate, anhydrous
TILETAMINE HYDROCHLORI	*Identification*/*B. Ultraviolet*	*USP42–NF37*	4347	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DE	*Absorption <197U>*							0.3 mg per mL. to: 0.03 mg per mL.
REAGENTS AND REFERENCE TABLES	SOLUTIONS/*0.01 M Edetate Disodium VS*	*USP42–NF37*	6179	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Standardization*: Change previously dried at 100° to: previously dried at 110°
CEFTIOFUR HYDROCHLORIDE	IMPURITIES/*High Molecular Weight Impurities*	*USP42–NF37*	857	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Analysis*: Change r_C = peak response of ceftiofur from the *Sample solution* (mg/mL) r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution* (mg/mL) to: r_C = peak response of ceftiofur from

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Sample solution* r_A = sum of the responses of all peaks that elute after ceftiofur from the *Sample solution*
PHENYLBUTAZONE INJECTION	*Assay*	*USP42–NF37*	3487	31-May-2019	1-Jun-2019	*NA*	*NA*	Change 350(*C*/*V*)(R_U/R_S) to: 714.3(*C*/*V*)(R_U/R_S)
DIDANOSINE	IMPURITIES/*Related Compounds*	*USP42–NF37*	1336	31-May-2019	1-Jun-2019	*NA*	*NA*	In *System suitability solution*: Change 0.5 mg/mL of of didanosine from USP Didanosine System Suitability Mixture RS in *Diluent* to: 0.5 mg/mL of USP Didanosine System

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DRONEDARONE TABLETS	PERFORMANCE TESTS/*Dissolution <711>*	*USP42–NF37*	1519	31-May-2019	1-Jun-2019	*NA*	*NA*	Suitability Mixture RS in *Diluent* In *Tolerances*/*30 min*: Change 20.0%–60.0% (*Q*) of the labeled amount of dronedarone free base to: 20.0%–60.0% of the labeled amount of dronedarone free base
GUANABENZ ACETATE	IMPURITIES/*Limit of 2,6-Dichlorobenzaldehyde*/*Chromatographic system*	*USP42–NF37*	2129	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Column*: Change 1.8-mm × 3-mm; to: 1.8-m × 3-mm;
SUMATRIPTAN SUCCINATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	4145	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Sumatriptan Succinate Related Impurities RS: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Mixture of sumatriptan succinate, [3-[2-(methylamino) ethyl]-1*H* -indo l-5-yl]-*N* -methylmethane sulfonamide maleate salt, sumatriptan succinate related compound C, [3 -[2-(dimethylami no-*N* -o xid e)ethyl]-1*H*-indol- 5-yl]-*N* -methylmethane sulfonamide, and [3-[2-(amin oethyl)]-1*H* -indo l-5-yl]-*N*-methyl methanesulfona mide. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide, sumatriptan succinate related compound C, [3-[2-(dimethylamino-*N*-oxide)ethyl]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1*H*-indol-5-yl]-*N*-methylmethanesulfonamide.
BACILLUS	ASSAY/	*USP42–NF37*	4749	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
COAGULANS CAPSULES	*Enumeration*							*diluent*: Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile containers as needed for preparing samples. *Trace mineral solution*: Prepare a solution containing
SALMETEROL INHALATION POWDER	IM PUR ITIES/*Organic Impurities*	*USP42–NF37*	Online	31-May-2019	1-Jun-2019	*NA*	*NA*	In Row 8 of Column 1 of *Table 3*: Change Hyrdoxynaphthoic acid to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Hydroxynaphthoic acid
CLOMIPHENE CITRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	1068	31-May-2019	1-Jun-2019	*NA*	*NA*	In USP Clomiphene Related Compound A RS: Change (*E*,*Z*)-2-[4-(1,2-Diphenylethyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride. to: (*E*,*Z*)-2-[4-(1,2-Diphenylvinyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride. Also known as (*E*,*Z*)-2-[4-(1,2-Diphenylethenyl)phenoxy]-*N*,*N*-diethylethanamine hydrochloride.
DOXORUBICIN	ASSAY/	*USP42–NF37*	1481	31-May-2019	1-Jun-2019	*NA*	*NA*	In the *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE	*Procedure*							Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
DULOXETINE DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*/*Table 2*	*USP42–NF37*	1527	31-May-2019	1-Jun-2019	*NA*	*NA*	In footnote a: Change This is a process impurity that is included in *Table 1* for identification purposes only. to: This is a process impurity that is included for identification purposes only.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PIPERAZINE PHOSPHATE	*Assay*	*USP42–NF37*	3549	31-May-2019	1-Jun-2019	*NA*	*NA*	Change Each mL of 0.1 N perchloric acid is equivalent to 7.953 mg of $C_4H_{10}N_2 \cdot 2HCl$. to: Each mL of 0.1 N perchloric acid is equivalent to 9.207 mg of $C_4H_{10}N_2 \cdot H_3PO_4$.
BACILLUS COAGULANS	ASSAY/ *Enumeration*	*USP42–NF37*	4746	31-May-2019	1-Jun-2019	*NA*	*NA*	In *Peptone diluent*: Change Dispense into sterile containers as needed for preparing samples. Trace mineral solution. Prepare a solution containing to: Dispense into sterile

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								containers as needed for preparing samples. *Trace mineral solution*: Prepare a solution containing
NEPHELOMETRY AND TURBIDIMETRY	5. FORMAZIN TURBIDITY STANDARDS	*USP42–NF37*	7059	26-Apr-2019	1-May-2019	*NA*	*NA*	In paragraph 1: Change *IUPAC Compendium of Chemical Technology,* to: *IUPAC Compendium of Chemical Terminology,*
FELODIPINE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP42–NF37*	1787	26-Apr-2019	1-May-2019	*NA*	*NA*	In the second variable definition list in *Analysis*: Change V_S = volume of the *Sample solution* withdrawn at each time point, *i*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: V_S = volume of the *Sample solution* withdrawn at each time point, *i* (mL)
LEVALBUTEROL INHALATION SOLUTION	IMPURITIES/*Organic Impurities*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 3 of *Table 3*: Change Levalbuterol — — — to: Levalbuterol 1.0 — —
THALIDOMIDE	*Assay*	*USP42–NF37*	4281	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Chromatographic system*: Change and the relative standard deviation for replicate injections is not more than 1.0%. to: and the relative standard deviation for the response ratio

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of thalidomide to phenacetin is not more than 1.0%.
REAGENTS AND REFERENCE TABLES	REAGENT SPECIFICATIONS	*USP42–NF37*	6104	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Ferric Nitrate*: Change [10421-48-4]. to: [7782-61-8].
PSEUDOEPHEDRINE HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*Revision Bulletin (Official March 01, 2019)*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In the *Figure 1* caption: Change (see *Drug Release <724>, Figure 4c*) to: (see *Drug Release <724>, Figure 5c*)
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In Row 2 of Column 3 of *Table 4*: Change $0.014^{?}/0.028_{?2S}$ *(USP41)* to: 0.014 AND In Row 3 of Column 3 of *Table 4*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	2518	26-Apr-2019	1-May-2019	*NA*	*NA*	Change 0.014 to: 0.014/0.028 AND In *Chromatographic system*/*Column*: Change 4.6-mm × 15-cm; 5-µm packing L7. [Note—Conditioning of the *Column* with *Solution A* and *Solution B* (80:20) for NLT 20 min is recommended prior to use.] to: 4.6-mm × 15-cm; 5-µm packing L7 In USP Levalbuterol Related Compound D RS: Change 5-{2-[(1,1-Dimet

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hylethyl)amino]-1-hydroxyethyl}-2-hydroxy-benzaldehyde. $C_{13}H_{19}NO_3$ 237.29 ?[NOTE—This may be available as the sulfate salt (2:1).]? (USP 1-May-2019) to: 5-[2-(*tert*-Butylamino)-1-hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67
MORPHINE SULFATE EXTENDED-	ADDITIONAL REQUIREMENTS/*USP*	*Revision Bulletin (Official November 01,*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Morphine Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RELEASE CAPSULES	*Reference Standards <11>*	*2018)*						Compound B RS: Change 2,2'-Bimorphine. $C_{34}H_{36}N_2O_6$ 568.66 to: 2,2'-Bimorphine trihydrate. $C_{34}H_{36}N_2O_6$? $3H_2O$ 622.72
INOSITOL	IM PURITIES/*Limit of Lead*	*USP42–NF37*	5776	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Standard lead solution*: Delete A comparison solution prepared on the basis of 100 µL of the *Standard lead solution* per g of substance being tested contains the equivalent of 1 part of lead per million parts of substance being tested.
PHARMACEUTICAL CALCULATIONS IN	10. ALLIGATION ALTERNATE	*USP42–NF37*	7831	26-Apr-2019	1-May-2019	*NA*	*NA*	In *10.2 Algebra Method*/*10.2.1 Calculating by*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PHARMACY PRACTICE	AND ALGEBRA METHODS FOR COMBINING MULTIPLE STRENGTHS OF THE SAME ACTIVE PHAR MACEUTICAL INGREDIENT							*using the algebra method/ Examples—Alge bra method*: In example *2*, in equations 1, 2, 3, and 4 in all instances: Change C_s to: Q_s AND In example 2, in equation 5: Change C_w to: Q_w
ATORVASTATI N CALCIUM	ADDITIONAL R EQUIREMENT S/*USP Reference Standards <11>*	*USP42–NF37*	410	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Atorvastatin Related Compound A RS: Change Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylca rbamoyl)-2-isop ropyl-4,5-diphen yl-1*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt. to: Calcium (3*R*,5*R*)-7-[2-isopropyl-4,5-diphenyl-3-(phenylcarbamoyl)-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2); Also known as Desfluoro impurity, or (3*R*,5*R*)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1*H*-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid, calcium salt.
IMIPRAMINE PAMOATE CAPSULES	ASSAY/ *Procedure*	*USP42–NF37*	Online	26-Apr-2019	1-May-2019	*NA*	*NA*	In *Solution A* and *Solution B* and *Diluent*: Change *Chromatographi*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								c acetonitrile to: Acetonitrile
LEVALBUTEROL INHALATION SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP42–NF37*	2520	26-Apr-2019	1-May-2019	*NA*	*NA*	In USP Levalbuterol Related Compound D RS: Change 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde; Also known as 5-[2-{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzene methanol. $C_{13}H_{19}NO_3$ 237.29 [NOTE: This Reference Standard is available as the benzesulfonic acid salt.] to: 5-[2-(*tert*-Butylamino)-1-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydroxyethyl]-2-hydroxybenzaldehyde sulfate (2:1) (salt); Also known as 5-[2-{(1,1-Dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1). $(C_{13}H_{19}NO_3)_2 \cdot H_2SO_4$ 572.67

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 12
- Page 13
- Page 14
- Page 15
- Page 16
- Page 17
- Page 18
- Page 19
- Page 20
- …
- Next page Next ›
- Last page Last »